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 Objective: Studies suggest clinical benefit of glutamine supplemented parenteral nutrition. 
The aim was to determine if the inclusion of 10g of glutamine as part of the nitrogen source of 
home parenteral nutrition (HPN) reduces infectious complications. 
Design: A double blind randomised controlled crossover trial. 
Setting: National centre for the treatment of patients on HPN.  
Subjects: 35 patients on HPN were recruited and 22 completed the study. 
Interventions: Patients were randomised to receive either standard HPN or glutamine 
supplemented HPN. Patients were assessed at randomisation, 3 and 6 months later then they 
were crossed over to the alternative HPN and reassessed at 3 and 6 months. Assessments 
included plasma amino acid concentrations, intestinal permeability and absorption, nutritional 
status, oral and parenteral intake, quality of life, routine biochemistry and haematology.   
Results: No difference was seen between the groups at randomisation. No difference was 
detected between the treatment phases for infective complications (55% in the standard 
treatment phase and 36% in the glutamine supplemented phase P=0.67). There were no 
differences in nutritional status, intestinal permeability, plasma glutamine concentrations or 
quality of life.  
Conclusion: Although limited by the sample size the study has shown that glutamine as part 
of the nitrogen source of parenteral nutrition can be given to patients on HPN for 6 months 
without any adverse effects.  
Sponsorship: Unrestricted grant from Fresenius Kabi 
Descriptors: glutamine, home parenteral nutrition, infective complications, intestinal 
permeability, TPN. 
 Introduction 
Glutamine is the most abundant free amino acid in extra- and intracellular compartments, 
contributing more than 50% of the body free amino acid pool (Krebs 1935). It is a major fuel 
for rapidly replicating cells such as immune cells (Calder 1994) and enterocytes 
(Windmueller 1982). Conventional parenteral nutrition solutions do not contain glutamine, as 
adults are considered able to synthesize glutamine from glutamate and glutamic acid (Rose 
1938). In addition, until recently, problems with stability and solubility have hindered its 
addition to parenteral nutrition. However, an increasing number of studies in humans suggest 
clinical benefits of glutamine supplementation in acutely unwell patients on exclusive 
parenteral nutrition. Glutamine supplementation appears to be beneficial following burns 
(Ogle et al, 1994) major surgery (Hammarqvist et al, 1989) bone marrow transplantation 
(Ziegler et al, 1992) sepsis and critical illness (Griffiths et al, 1997) due to its effect on 
nitrogen balance (Morlion et al, 1998), immune function (O’Riordan et al, 1994) and 
intestinal permeability (van der Hulst et al, 1993). During catabolic states, glutamine 
concentration in the intracellular pool falls rapidly because glutamine serves as a fuel for 
stimulated lymphocytes, macrophages (Calder 1994) and intestinal mucosal cells 
(Windmueller 1982). Patients on home parenteral nutrition (HPN) are susceptible to recurrent 
central venous catheter (CVC) infections and animal studies have demonstrated that 
parenteral glutamine reduces CVC infections (McAndrew et al, 1999). It is therefore 
hypothesized that HPN patients may benefit from glutamine supplementation. To date, no 
studies have been undertaken to investigate the effect of glutamine supplementation on 
infective complications in patients on long term HPN. Safety data exist both for normal 
volunteers at a dose of 0.57g/kg/day over 5 days, and for bone marrow transplant patients 
receiving glutamine supplemented parenteral nutrition to approximately the same level over 
28 days. Safety was considered good in these contexts (Ziegler et al, 1990). However, a study 
 of patients on HPN receiving 0.285g/kg/day of parenteral glutamine over four weeks resulted 
in abnormal liver function tests, which necessitated the discontinuation of glutamine 
supplementation in two patients (Hornsby-Lewis et al, 1994). 
Patients and methods 
The study was a randomised, double blind, controlled crossover trial carried out from June 
2001 to December 2002. All adults on HPN under the care of the Nutrition and Intestinal 
Failure Clinic at St Mark’s Hospital were considered for the study. Patients were excluded if 
they did not consent, were due to undergo planned surgery, were pregnant or had severe liver 
or renal failure or an inborn error of amino acid metabolism (e.g. phenylketonuria).  
Our primary endpoint was infective complications. Our secondary endpoints were intestinal 
permeability, quality of life and plasma amino acid concentrations during the two phases of 
the study.  The crossover design was chosen due to the heterogeneous population being 
studied so that patients could act as their own control.  
Protocol 
After written consent had been obtained, patients were randomised to receive either standard 
HPN (for which the amino acid solution was Intrafusin 22, Fresenius Kabi, Stockholm) or 
glutamine supplemented HPN (for which the amino acid solution was Glamin, Fresenius 
Kabi, Stockholm). A pharmacist performed the randomisation by opening sealed envelopes 
and allocated patients to receive either glutamine supplemented HPN or standard HPN first. 
The homecare companies who deliver HPN did not display the amino acid source on the bag 
label. All other investigators, including the statistician who analysed the data, were blind to 
the randomisation process. Patients were assessed as outpatients at randomisation, and 3 and 6 
months later. After the 6-month assessment, the patients were crossed over onto the 
alternative amino acid solution and reassessed 3 and 6 months later (Figure 1). Assessments 
included an examination of plasma amino acid concentrations, intestinal permeability and 
 absorption, nutritional status, oral and parenteral nutrient intake, quality of life and routine 
biochemistry and haematology.   
Parenteral Nutrition 
This was a comparison of two commercially available amino acid solutions with similar 
nitrogen content. An exact isonitrogenous comparison was not possible in this study and so 
we compared our standard amino acid solution with a glutamine supplemented solution. Table 
1 shows the composition of the two parenteral amino acid solutions. The glutamine was 
present as a dipeptide with glycine. The energy and nitrogen content of the HPN for each 
patient were not altered during the study so that individual patients remained isonitrogenous 
and isocaloric during the study period. All patients received at least 11g of nitrogen 
intravenously on the days they received HPN. For patients not receiving HPN every day an 
average intake of nutrients per day were calculated. From these figures, patients received a 
mean intake of 0.14 ± 0.04g /kg/day of glutamine (range 0.08 – 0.24g/kg/day) during 
glutamine supplementation. Parenteral fluid, electrolytes, trace elements and vitamins were 
prescribed according to the patient’s individual requirements.  
Patients on HPN are trained to report any signs or symptoms of a possible infection, which is 
then investigated. During the trial if patients developed signs or symptoms of catheter related 
sepsis (chills, flu-like symptoms or fever of >38
0
 C, rigors) central and peripheral blood 
cultures were obtained, sent to microbiology for culture and the patient was screened for other 
causes of infection. Any positive central blood culture was recorded as an infective 
complication and the organism noted. Parenteral nutrition is stopped and peripheral fluids are 
commenced whilst awaiting the results of the cultures. Patients are administered appropriate 
antibiotics (according to sensitivities) via the CVC for one week. Parenteral nutrition is then 
restarted and patients are monitored for signs and symptoms of catheter related sepsis as 
detailed above.  
 Quality of life 
Quality of life measurements were assessed using the SF-36 and EuroQol questionnaires, 
which have previously been used to assess patients on HPN (Richards et al, 1997).  The SF-36 
is designed to examine eight aspects of life and scores each domain on a scale of 0-100%. It 
was scored according to the published scoring manual (Ware 1993). The EuroQol is a simple 
generic measure designed to assess health using descriptive statements. These statements 
generate a single numeric index to estimate quality of life status used for clinical evaluations 
of health. It also includes a visual analogue scale from 0 to 100 with 0 being worst imaginable 
health state to 100 being best imaginable (Dolan et al, 1995). Both questionnaires are 
designed for self-completion. 
Nutritional status and oral intake 
The assessment of nutritional status was performed using anthropometry including 
measurement of height, weight and calculation of body mass index (BMI), mid-arm 
circumference (MAC), tricep skinfold thickness (TST) and calculation of mid-arm muscle 
circumference (MAMC). This was undertaken by a trained research dietitian using 
standardized procedures (Gurney & Jelliffe 1973). In the week before each assessment, 
patients were asked to record their food and fluid intake over a 3-day period using a diary. 
The diaries were verified by the dietitian at an out patient visit and then the description of 
food was converted to weight in grams using a photographic atlas of food portion sizes 
(Nelson et al, 1997). A computerized nutrient analysis program was used to calculate the 
energy, protein, fat and carbohydrate content of the three days and the average was calculated 
(COMP-EAT, Carlson Bengston Consultants Limited, London).  
Intestinal permeability and absorptive capacity 
The differential urinary excretion of lactulose and L-rhamnose (L/R ratio) was used as a 
specific index of intestinal permeability and the differential urinary excretion of rhamnose and 
 3-O-methyl-D-glucose (R/3OMG ratio) was used as an index of intestinal carbohydrate 
absorptive capacity. After an overnight fast, the patient was instructed to empty the bladder 
and to drink a test solution containing 0.2g 3-O-methyl-D-glucose, 1g L-rhamnose and 5g of 
lactulose made up to 100ml with tap water. Food and fluids were withheld until 2 hours after 
ingestion of the solution. Over the next 5 hours, patients collected their urine into containers 
containing 5ml 10% thyme. The volume of the urine collected was recorded and a 20ml 
aliquot removed from the final collection and stored at -70
o
C prior to analysis of urinary 
sugars by thin layer chromatography (Menses & Crane 1998). 
Additional variables/measurements 
Routine haematology and biochemistry tests were performed at each visit. Patients infuse 
HPN overnight and then travel to St Mark’s for their out patient appointments and so we were 
unable to standardise the timing of the samples for glutamine analysis but this would have 
been within 6-8 hours post infusion. An extra blood sample was taken in a heparins tube and 
spun at 2000g for 10 minutes. The plasma was then stored at -70
o
C prior to analysis of amino 
acids by high performance liquid chromatography (Sherwood 1990).    
Statistics 
Statistical analyses were performed at randomisation to ensure that the randomisation process 
was effective. The statistics reported are mean ± standard deviations (SD) in each group, 
together with the p-value resulting from the t-test for those variables found to be normally 
distributed. For variables found not to be normally distributed, the median and inter-quartile 
range (IQR) was reported, together with the p-value from the Mann-Whitney test. 
A paired t-test was used for parametric data and a Mann-Whitney test for non-parametric 
variables to compare patients in the two phases of the study. All values are given as mean ± 
SD together with the P-value for those variables found to be normally distributed. For 
variables not normally distributed, the median and IQR is reported, together with the P-value 
 from the Mann-Whitney test. We were unable to incorporate a washout period as part of the 
trial as patients are dependent on parenteral nutrition. Any carry over effect, due to the lack of 
a washout period, was assessed using the difference in results between the periods for each 
subject and comparing between treatment orders using a paired t-test. All analysis was 
restricted to patients who had completed both periods of the study. Fischer’s exact test was 
used to assess if the number of CVC infections varied between the two treatments. 
Informed consent was obtained from the patient and the study protocol was approved by the 
Harrow Local Research Ethics Committee (2654). 
Results 
Thirty-five patients were entered into the study. Twenty-two completed both periods of the 
study. Five patients no longer required HPN of which four remained on intravenous fluids and 
electrolytes, four withdrew consent and three died. One patient was withdrawn due to 
protocol deviation, as she had not received any parenteral nutrition for over two months 
during an inpatient stay for recurrent infections. The allocation of the patients who did not 
complete the study is shown in Figure 2. There were no statistically significant differences at 
baseline between patients allocated to receive glutamine supplemented HPN first and those 
who were allocated to receive standard HPN first (Tables 2 and 3) with the exception of more 
patients with an ileostomy being randomised to the standard HPN first (P=0.04) showing that 
the randomisation process was successful.    
Complications 
Complications were classified into infective, non-infective, vascular and disease related 
(Table 4). There was no significant difference in the total rate of any complications during the 
two phases of the study (P=0.67). Patients receiving standard HPN had 0.1 
infections/patient/month compared to 0.06 infections/patient/month on glutamine 
supplemented HPN. One patient had their CVC removed and replaced. Of the other infective 
 episodes 3 patients had a subsequent re-infection of the same CVC with the same organism 
which may in one case have been due to concurrent dental treatment. The other two patients 
had a repeat infection but this occurred 7 months later. There were three deaths during the 
study of which one occurred during glutamine supplemented HPN and two during the 
standard HPN phase but this difference was not statistically significant. Causes of death 
included cancer (n=2) and respiratory failure not thought to be related to the study (n=1). No 
non-catheter related infective complications occurred during the study period.   
Quality of life 
Twenty-one patients completed the SF-36 and EuroQol questionnaires at each visit during the 
study period. Glutamine supplemented HPN had no obvious effect on quality of life in these 
patients at any point during the study (Table 5).   
Nutritional status and oral intake  
There was no significant change in nutritional status during the study (Table 5). Patients in 
both groups had similar intakes of oral protein and parenteral nitrogen throughout the study 
period.  The addition of glutamine to HPN had no effect on oral intake at any point during the 
trial period (data not presented).  
Intestinal permeability and absorption 
Results were available for twenty patients who completed the study, as two patients were non-
compliant with this aspect of the study. There were paired data available on thirteen patients. 
The median intestinal permeability (lactulose/rhamnose) ratio on glutamine supplemented 
parenteral nutrition was 0.91 (0.37, 1.45) compared to 0.39 (0.18, 0.79) on standard parenteral 
nutrition. In addition, the mean intestinal absorption index (rhamnose/3-O- methyl-D-glucose) 
on glutamine was 0.10 ± 0.06 compared to 0.12 ± 0.05 on standard parenteral nutrition. 
Neither of these results showed a statistically significant difference. Therefore, the intestinal 
 permeability ratio and absorptive index were not affected by the addition of glutamine (Table 
5).  
Biochemistry and haematology 
The addition of glutamine had no significant effect on any of the variables measured (data not 
presented). Liver function tests were not significantly affected by the addition of glutamine 
(Table 5).  
Plasma amino acid concentrations 
The concentrations of phenylalanine and histidine were significantly higher during glutamine 
administration, whereas the levels of serine and proline were significantly higher during 
standard parenteral nutrition administration as would be expected from the profile of amino 
acids in the two solutions. Glutamine supplementation had no significant effect on plasma 
glutamine concentrations (Table 6).  
Discussion 
The debate on the efficacy of glutamine in artificial nutrition continues with many studies and 
reviews providing conflicting results and opinions (Buchman 2001, Novak et al, 2002, 
Garcia-de-Lorenzo et al, 2003).  Furthermore, in 2003 the Canadian clinical practice 
guidelines for nutrition support in ventilated, critically ill adult patients were published which 
recommend the addition of glutamine to parenteral nutrition. However many difficulties are 
faced when attempting a systematic review or meta-analyses including the use of a 
heterogeneous population which may include children or the inclusion of patients after 
elective surgery who may not be considered critically ill such as the patients in this study 
(Heyland 2003). Despite studies in animals demonstrating that parenteral glutamine reduces 
CVC infections (McAndrew et al, 1999) no benefit was observed in the present long term 
study (P=0.67). The species of infective organisms causing CVC infections (Table 4) were 
similar to those previously reported HPN patients (O’Keefe et al, 1994). It is difficult to 
 compare our study with previous studies on the efficacy of glutamine supplementation given 
that this is the first long-term study of patients on HPN. As can be seen in Table 2, these 
patients had a mean BMI in the normal range and were stable and living at home. They were 
not critically ill or undergoing surgical or medical procedures, which may have increased their 
requirement for glutamine, although some patients had baseline plasma glutamine 
concentrations below normal and abnormal intestinal permeability (Table 2).  
Previous studies have shown both a positive (Detsky et al, 1986) and a negative (Jeppesen et 
al, 1999) impact of standard HPN on quality of life. In patients’ undergoing bone marrow 
transplant a significant improvement in mood with parenteral glutamine supplementation was 
observed. The authors hypothesized that glutamine may influence patients’ feeling of 
wellbeing either directly by affecting central nervous system neurotransmitters or through its 
effect on protein status of patients. However, in the present study, no significant differences 
was observed in any of the assessed quality of life indices, including mental health, during the 
two phases of the study. This may have been due to the low dose of glutamine used in this 
study, 0.14 ± 0.04g/kg/day in comparison to 0.57g/kg/day, the use of different questionnaires 
or because different types of patients were studied (Young et al, 1993).   
The permeability ratio associated with glutamine supplementation observed in the study is 
contrary to the findings of van der Hulst et al who found that glutamine supplemented 
parenteral nutrition (0.23g/kg/day) prevented deterioration of gut permeability compared to 
standard parenteral nutrition in patients with gastrointestinal disease (van der Hulst et al, 
1993). There were no significant differences in permeability ratio on glutamine supplemented 
or standard HPN. All of the patients in the present study took some form of nutrition orally, 
and it may be that the provision of parenteral glutamine in this group is not as effective as 
when patients receive solely parenteral nutrition as often occurs during critical illness and 
post operatively. It was not possible to calculate the contribution of patients’ oral glutamine 
 intake as this was impractical in an out patient setting. However, as their oral protein intakes 
were similar throughout the study period it can be postulated that their oral glutamine intake 
would not be significantly different and would contribute the same effect in both phases of the 
crossover design. This study may provide evidence that at this dose glutamine supplemented 
HPN does not improve small bowel permeability in stable HPN patients who take nutrition 
orally. Five patients had undetectable urinary rhamnose concentrations, which prevented 
calculation   of the permeability ratio. The rhamnose concentrations are low in this group of 
patients as the majority had a short bowel, decreasing the absorption of all four of the test 
carbohydrates used in the study. This means that lactulose and rhamnose are affected equally 
and so the ratio should be preserved. Previous investigators have demonstrated that this test 
can be reliable in patients with short bowel syndrome (D’Antiga et al, 1999). Our results 
agree with the findings of Ockenga who showed that the addition of 0.2g/kg/day of glutamine 
to 24 patients with inflammatory bowel disease did not alter intestinal permeability or plasma 
glutamine concentrations (Ockenga et al, 2005).   
Of the 5 patients who no longer required HPN, 4 of them continued on IV fluids and 
electrolytes (3 patients with Crohn’s and one mesenteric infarction) presumably due to 
intestinal adaptation. Of these 4 patients, there was no difference between patients randomised 
to glutamine supplemented HPN first (n=2) or standard HPN first (n=2) and so the addition of 
glutamine had no effect on the intestinal adaptation and has not been reported in the results. 
One had surgery to reconnect his remaining bowel which allowed him to be independent from 
HPN. The level of parenteral glutamine supplementation in the present study was lower than 
that used in a previous study in which 3 out of 7 HPN patients given 0.285g/kg/day of 
parenteral glutamine for 4 weeks developed abnormal liver function tests (Hornsby-Lewis et 
al 1994). These patients had stable LFT’s for one year before the study commenced and had 
no changes made to their HPN prescriptions during the study with all abnormal LFT’s 
 returning to baseline 2 weeks after stopping the glutamine. No biopsy or ultrasound was 
undertaken and patients were not rechallenged. There have been no further studies with 
glutamine in patients on HPN as studies have concentrated on acutely unwell patients.  It was 
shown that the level of glutamine administered in our study did not cause an elevation in 
LFT’s and may be given to patients on long term HPN. However, it is possible that as a result 
the dose was not adequate to exert a potential benefit.  
It is interesting to note that plasma glutamine concentrations were below normal in some 
patients’ at baseline (Table 2) but we were unable to demonstrate a significant difference in 
the plasma glutamine concentrations during the course of the study (Table 6). This is 
concordant with the findings from a study by van Acker who studied glutamine supplemented 
parenteral nutrition in 18 patients undergoing gastrointestinal surgery. They showed that 0.21 
± 0.01g/kg/day of parenteral glutamine did not significantly increase plasma glutamine 
concentrations after 8-10 days of treatment (van Acker et al, 2000). However, in bone marrow 
transplant patients, Ziegler showed that plasma glutamine concentrations rose by 40% 
following glutamine supplemented parenteral nutrition in comparison to standard nutrition 
(P<0.0001) and concentrations remained elevated whilst supplementation continued for 21 
days (Ziegler et al, 1992). This may reflect the much higher dose of glutamine (0.57g/kg) 
used in this study.  In the present study, significant differences in the plasma concentrations of 
other amino acids were observed between the two groups (Table 6) and it seems likely that 
these differences can be attributed to the different composition of the two amino acid 
solutions used (Table 1). The higher serine content of the standard HPN probably accounts for 
higher concentrations in patients whilst on the standard HPN. Parallel differences may also 
explain the significant differences in phenylalanine, histidine and proline concentrations. 
However, this is not seen with glutamine and the explanation for this is not known. It may be 
that the dose given in this study was inadequate or that the additional glutamine provided was 
 utilised. It was thought that the glutamate, present as a dipeptide with lysine, in the standard 
HPN (Table 1) could have been synthesized to glutamine via glutamine synthetase, which 
may have resulted in the maintenance of plasma concentrations of glutamine in patients 
during the period of standard HPN infusion. It is known however, that glutamate is not a good 
substitute for glutamine as it has been shown that glutamate is rapidly metabolized and fails to 
increase plasma concentrations of glutamine in septic patients and healthy volunteers 
(Kingsland et al, 1981). 
The addition of 0.14 ± 0.04g/kg/day of glutamine to HPN has been shown to cause no adverse 
effects in this patient population. There was a numerical reduction in the number of infective 
complications during glutamine supplementation, but this did not reach statistical 
significance. There were no differences in quality of life, plasma glutamine concentration, 
intestinal permeability or absorption. We recognise that the study is underpowered and that 
the small number of patients limits the power of detecting significant changes. However, as 
no changes or trends were observed at this dose of glutamine it appears that glutamine confers 
no benefit with regards to CVC infections, plasma glutamine concentrations, intestinal 
permeability or absorption and so routine supplementation of HPN with glutamine at this dose 
cannot currently be recommended. Further studies might productively consider higher 
glutamine doses during an infective episode as part of a multi-centre trial or in patients who 
experience multiple CVC infections. Studies could be targeted to patients who are known to 
have depleted plasma glutamine concentrations. 
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 Table 1 Composition of glutamine supplemented HPN and standard HPN per 500ml. 
 
Amino acid   Glutamine supplemented HPN (g) Standard HPN (g) 
Indispensable 
L-leucine    3.95     2.85 
L-isoleucine    2.80     2.10 
L-lysine     4.5     6.75 
L-valine    3.65     2.35 
L-phenylalanine   2.93     2.05 
L-histidine    3.40     1.75 
L-threonine    2.80     2.70 
L-methionine    2.80     2.70 
L-tryptophan    0.95     1.05 
Dispensable 
L-alanine    8.00               13.0 
L-arginine    5.65     7.00 
Glutamic acid    2.80     3.75 
L-glutamine    10.0       - 
Glycine    5.60     7.80 
L-proline    3.40     7.05 
L-serine    2.25     7.05 
L-tyrosine    1.14     1.13 
L-cysteine      -     0.35 
Aspartic acid    1.70       - 
Total L-amino acids (g)  77.0     76.2 
 Total nitrogen (g)   11.2     11.4 
Table 1 Composition of glutamine supplemented HPN and standard HPN per 500ml 
(cont).  
Energy content (kcal)   270     300 
pH           5.80     5.20 
Osmolality (mosmol/kg water) 1140     1400 
 
 Table 2 Comparison of baseline data of the two groups at randomisation (demographics, 
anthropometrics, oral and parenteral nutrition, plasma glutamine, intestinal 
permeability and absorption). 
Glutamine supplemented Standard HPN      P value 
                                                      HPN first (n=11)                 first (n=11) 
Male/female        5/6    4/7   0.64 
Age (years)            51.5 ± 12.1       55.5 ± 12.8   0.46 
Aetiology           0.67 
Crohn’s disease        5                                          3    
Mesenteric infarct        2     2    
Other *         4     6    
Length of small bowel         0.84 
<50 cm         3     2    
50-100 cm         3    4    
>100cm         5    5    
Type of stoma          0.04 
Jejunostomy                    1     0    
Ileostomy         0    5    
Colostomy         1    1    
Colon in continuity                   9    6    
Time on HPN (months)**              51 (11, 99)       28 (13, 83)              0.65 
Nutritional status 
Weight (kg)            57.9 ± 11.1      61.7 ± 10.2             0.41  
Body mass index (kg/m
2
)          21.1 ± 3.0      22.1 ± 2.5                           0.41 
 Table 2 Comparison of baseline data of the two groups at randomisation (demographics, 
anthropometrics, oral and parenteral nutrition, plasma glutamine, intestinal 
permeability and absorption). (cont) 
Tricep skinfold thickness (mm)       11.2 ± 3.7      14.0 ± 5.7   0.18 
MAMC (cm)                                    21.8 ± 4.0      23.3 ± 2.6    0.30 
Oral nutrition 
Energy (kcal)           1244 ± 606     1547 ± 949   0.42 
Protein intake (g)              47 ± 28                    55 ± 31   0.58 
Fat (g)                50 ± 22.         73 ± 46   0.19 
Carbohydrate (g)            161 ± 92       183 ± 116   0.64 
Parenteral nutrition            
Energy (kcal)           1376 ± 511     1204 ± 484   0.43 
Nitrogen (g)              9.3 ± 2.1        9.5 ± 3.4   0.83 
Lipid (kcal)             202 ± 124                  173 ± 163              0.65 
Glucose (kcal)           1177 ± 419                1031 ± 426              0.64 
Glutamine (g/kg/day)                       0.14 ± 0.07            0.15 ± 0.04   0.68 
Frequency of HPN (days/week)**      6 (5, 7)          6 (5, 7)   0.95 
Plasma glutamine (µmol/L)           481 ± 106       459 ± 90                  0.61 
Intestinal permeability ratio          0.58 ± 0.43      0.39 ± 0.26              0.32 
Intestinal absorption index          0.13 ± 0.06       0.14 ± 0.09              0.81 
*includes visceral myopathy, scleroderma, radiation enteritis, pseudo-obstruction, familial 
adenopolyposis, sclerosing peritonitis and fistulae. 
Value presented as mean ± SD or ** median (IQR) 
 
 Table 3 Comparison of baseline data of the two groups at randomisation (quality of life  
and liver function tests)  
            Glutamine      Standard HPN       P value 
                                      supplemented HPN first (n=11)            first (n=11) 
SF-36   
           Health perception  41 ± 25   40 ± 23  0.90 
           Physical function  66 ± 32   45 ± 16  0.07 
           Role limiting physical*           38 (0, 100)   25 (0, 50)  0.34 
           Role limiting emotional*        100 (0, 100)           100 (67, 100)             0.84  
           Social functioning   68 ± 30                60 ± 28  0.57 
           Mental health                         72 ± 15    73 ± 16  0.87   
           Body pain                      68 ± 27    56 ± 25             0.30  
           Energy/fatigue               49 ± 26   44 ± 23  0.62 
   EuroQol  - index                 0.68 ± 0.21           0.67 ± 0.15  0.87 
            - visual analogue scale   63.7 ± 18.1           67.4 ± 10.3  0.57 
Liver function tests   
    ALT (10-50IU/L)   49 ± 29   43 ± 32  0.64 
    AP* (40-135IU/L)                111 (74, 125)   154 (109, 401) 0.11 
    Bilirubin* (1-17µmmols/L) 8 (6, 12)   8 (4, 9)  0.25 
    Albumin (35-50g/L)  41 ± 4.1   39 ± 2.4  0.18 
ALT=alanine transferase, AP=alkaline phosphatase 




 Table 4 Complications in the 6-month period on each HPN solution in 22 patients who 
completed the study 
                       Glutamine supplemented HPN           Standard HPN                 P value 
Infective              Klebsiella sp (n=1)                           Klebsiella sp (n=2)                0.67  
                             Staph aureus (n=1)                           Pseudomonas (n=2)                           
                             Staph epidermidis (n=2)                  Staph epidermidis (n=2)    
Non- infective     CVC resistance to flushing (n=1)    Occluded CVC (n=1)             1.00 
                             CVC fracture (n=1)       CVC displacement (n=1)    
Vascular             IVC* stenosis (n=1)                         SVC** stenosis (n=1)            1.00 
Disease related  Small bowel obstruction (n=1)          None                1.00  
* Inferior vena cava ** Superior vena cava 
 
 
 Table 5 Treatment effect of the addition of glutamine to HPN on quality of life, 
nutritional status, intestinal permeability and absorption and liver function tests. 
Outcome   Treatment effect 95%CI        P value 
Quality of life (n=21) 
SF-36   
            Health perception                     2.9  -2.3, 8.2  0.26 
            Physical function                    -2.1  -8.3, 4.1  0.48 
            Role limiting physical            -6.7  -28.2, 14.8  0.52 
            Role limiting emotional           4.4  -16.4, 25.2  0.66 
Social functioning  1.8  -12.3, 15.8  0.80 
Mental health   2.5  -4.4, 9.4  0.46 
Body pain   2.8  -7.9, 13.6  0.59 
Energy/fatigue                        -1.6  -9.5, 6.4  0.69 
EuroQol - index                                -0.02  -0.071, 0.031  0.42 
                - visual analogue scale       1.04  -6.99, 9.07  0.79 
Nutritional status (n=22) 
Weight (kg)    -0.95  - 2.47, 0.56  0.2 
Body mass index (kg/m
2
)  -0.36  -0.84, 0.13  0.14 
Tricep skinfold thickness (mm) -0.36  -1.00, 0.28  0.25 
MAMC (cm)               -0.33  -0.87, 0.22  0.22 
Intestinal permeability ratio (n=13)     0.52  -0.06, 1.11  0.07 
Intestinal absorption index (n=13)     -0.008  -0.024, 0.009       0.32 
Liver function tests (n=22) 
ALT      10.9  -2.6, 24.4  0.11 
AP     3.5  -19.5, 26.4  0.76 
 Table 5 Treatment effect of the addition of glutamine to HPN on quality of life 
nutritional status, intestinal permeability and absorption and liver function tests. (cont) 
Bilirubin              -0.54  -4.01, 2.91  0.75 
Albumin              -0.27  -1.75, 1.2  0.70 
ALT=alanine transferase, AP=alkaline phosphatase 
 Table 6. Treatment effect of the addition of glutamine to HPN on plasma amino acid 
concentrations (µmol/l) in 22 patients who completed the study  
Amino acid                Glutamine    Standard HPN  Treatment effect P value 
                               supplemented HPN            (95% CI) 
   
Leucine   98.2 ± 23.8  99.4 ± 23.6 -1.27 (-8.47, 5.93)    0.72   
Isoleucine*              58.0 ± 11.7  58.5 ± 11.7 -0.44 (-4.04, 3.16)    0.80 
Lysine             185.7 ± 44.3                172.6 ± 43.4       13.1 (-0.5, 26.6)    0.72 
Valine            187.1 ± 37.7           178.4 ± 39.1    8.8 (-6.6, 24.1)    0.25 
Phenylalanine             59.8 ± 12.7                  54.8 ± 9.2         5.07 (0.7, 9.44)    0.02 
Histidine**   82.9 ± 17.6                  67.2 ± 11.9       31.4 (6.4, 56.3)    0.02 
Threonine            131.3 ± 47.7           121.7 ± 47.5       9.9 (-13.1, 32.5)    0.39   
Methionine              26.9 ± 9.9  24.5 ± 7.4  2.43 (-0.32, 5.18)    0.08 
Alanine            358.9 ± 86.3           375.5 ± 91.8      -16.6 (-16.6, 18.4)    0.33   
Arginine              63.5 ± 15.4             68.7 ± 21.9  -5.1 (-13.7, 3.4)              0.23  
Glutamine            471.6 ± 75.4                466.3 ± 78.1       5.3 (-30.8, 41.3)           0.76  
Glycine            327.3 ± 84.2           355.2 ± 88.3      -27.0 (-64.8, 9.1)    0.13 
Proline**            205.9 ± 48.8                253.9 ± 75.1      -95.9 (-188.8, -3.4)    0.04 
Serine    98.3 ± 23.2                116.2 ± 30.8      -17.9 (-28.0, -7.8)    0.001 
Tyrosine   52.4 ± 12.8  50.1 ± 13.6    2.30 (-3.57, 8.16)    0.42 
Cysteine   2.48 ± 1.7                      2.2 ± 1.3         0.27 (-0.08, 0.63)    0.13 
* n=21 **n=12 
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